Lilly Strikes Up to $3.35B Discovery Deal with China's InnoCare
- Eli Lilly signed a discovery-stage collaboration and licensing deal with Beijing-based InnoCare Pharma worth up to $3.35 billion.
- Terms include up to $100 million upfront, up to $3.25 billion in milestones, and royalties, as InnoCare hunts compounds against up to five undisclosed targets.
- It marks Lilly's fourth China-biotech deal since early 2025, after Insilico Medicine, Innovent Biologics and Haisco.
💡 Points
Fourth China-sourced discovery deal for Lilly since early 2025 — this is deliberate strategy, not opportunism: outsourcing early-target risk to lower-cost Chinese biotech engines. The $100M upfront against $3.35B total (~3%) is a cheap option on unproven targets, not a derisked buy. China's shifting from manufacturing base to discovery pipeline for Big Pharma.
In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B ↗